• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Sonus names marketing VP

Article

Ultrasound contrast agent developer SonusPharmaceuticals announced this month that it has appointed TerryE. Willard as vice president of marketing and business development.Willard was formerly director of worldwide marketing in the

Ultrasound contrast agent developer SonusPharmaceuticals announced this month that it has appointed TerryE. Willard as vice president of marketing and business development.Willard was formerly director of worldwide marketing in the radiopharmaceuticalsdivision of Du Pont Merck Pharmaceutical. He also held positionsat American Hospital Supply, where he developed an understandingof the injectable drug market, which will be key to marketingSonus' agents, according to the company.

Sonus, of Costa Mesa, CA, is developing intravenous ultrasoundcontrast agents based on a dodecafluoropentane-based emulsion.The company has filed an investigational new drug (IND) applicationwith the Food and Drug Administration for EchoGen, a cardiac contrastagent (SCAN 1/19/94).

Related Videos
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Assessing the Impact of Radiology Workforce Shortages in Rural Communities
Emerging MRI and PET Research Reveals Link Between Visceral Abdominal Fat and Early Signs of Alzheimer’s Disease
Reimbursement Challenges in Radiology: An Interview with Richard Heller, MD
Nina Kottler, MD, MS
The Executive Order on AI: Promising Development for Radiology or ‘HIPAA for AI’?
Related Content
© 2024 MJH Life Sciences

All rights reserved.